drugset / Trial / NCT02259998

Pharmacokinetics of Two Different Persantin® Sugar Coated Tablets in Healthy Male Volunteers

NCT02259998

Phase 1 Completed 30 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

To investigate the relative bioavailability of the proposed formulation of PERSANTIN® compared to the present commercial formulation.

Timeline

Start
2001-10
Primary completion
2001-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dipyridamole Other / unclassified 75 mg Oral

Indications

No indication recorded.